Ann: Prospectus, page-72

https://app.sharelinktechnologies.com/announcement/asx/4dc426c72e10af50f326a4edc142a596
+ 28 days after treatment for Primary Endpoint
https://clinicaltrials.gov/study/NCT06055439

I note, there are a few more goals to be kicked before end of calendar year 2024 according to the latest (and also previous presentations):

• CLTX new trial design implementation (with subsequent enrollment to recommence),
• Advent AML preliminary data presentation.

OR



https://app.sharelinktechnologies.com/announcement/asx/50a1051dbb06df0b912bdb83e8028534

I note also the comment "Partner or License to Big Pharma" after Phase 2 Efficacy results of 70 patients presentation in what is estimated to be from end of calendar year 2025 onwards.
Estimates and of course timelines are subject to change.